TSE:MDP Medexus Pharmaceuticals (MDP) Stock Price, News & Analysis C$5.07 -0.12 (-2.31%) As of 09/23/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsInsider Trades About Medexus Pharmaceuticals Stock (TSE:MDP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MDP alerts:Sign Up Key Stats Today's RangeC$5.05▼C$5.2150-Day RangeC$4.78▼C$5.4552-Week RangeC$2.51▼C$5.50Volume25,962 shsAverage Volume47,312 shsMarket CapitalizationC$159.33 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of hematology and hematology-oncology and rheumatology and allergy. Read More Receive MDP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDP Stock News HeadlinesMedexus Pharmaceuticals (TSE:MDP) Stock Price Down 2.3% - Should You Sell?September 24 at 1:41 AM | americanbankingnews.comMedexus Pharmaceuticals Inc.: Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to DateAugust 10, 2026 | finanznachrichten.deBezos… DOOMEDA single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X combined - aimed at the $25 trillion AI industry. James Altucher says the plan could cut Amazon out of the AI race and disrupt Blue Origin, with a key deadline landing September 25.September 24 at 1:00 AM | Paradigm Press (Ad)Medexus Pharmaceuticals Inc.: Medexus Schedules First Fiscal Quarter 2027 Conference CallJuly 30, 2026 | finanznachrichten.deMedexus Pharmaceuticals Inc.: Medexus Announces Fiscal Year 2026 Results, Demonstrating Continued Momentum and Strong Product-Level Performance of GRAFAPEX (treosulfan) for ...June 26, 2026 | finanznachrichten.deShareholders in Medexus Pharmaceuticals (TSE:MDP) are in the red if they invested five years agoNovember 10, 2025 | finance.yahoo.comEarnings To Watch: Medexus Pharmaceuticals Inc (TSX:MDP) Reports Q1 2026 ResultAugust 14, 2025 | finance.yahoo.comMedexus Pharmaceuticals Inc. (MDP) Stock Price Today - WSJJuly 15, 2025 | wsj.comSee More Headlines MDP Stock Analysis - Frequently Asked Questions How have MDP shares performed this year? Medexus Pharmaceuticals' stock was trading at C$2.91 at the beginning of 2026. Since then, MDP stock has increased by 74.2% and is now trading at C$5.07. How do I buy shares of Medexus Pharmaceuticals? Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Medexus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Medexus Pharmaceuticals investors own include AutoZone (AZO), Cisco Systems (CSCO), Facedrive (FDVRF), Intel (INTC), kneat.com (KSI), NIO (NIO) and Nanotech Security (NTS). Company Calendar Today9/23/2026AGM 20269/24/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolTSE:MDP CIKN/A Webwww.medexus.com Phone877-633-3987FaxN/AEmployees90Year FoundedN/AProfitability EPS (Trailing Twelve Months)C($0.07) Trailing P/E RatioN/A Forward P/E Ratio31.04 P/E GrowthN/ANet IncomeC$3.26 million Net Margins-2.29% Pretax MarginN/A Return on Equity-4.69% Return on Assets4.89% Debt Debt-to-Equity Ratio54.62 Current Ratio1.30 Quick RatioN/A Sales & Book Value Annual SalesC$103.30 million Price / Sales1.54 Cash FlowN/A Price / Cash FlowN/A Book ValueC$1.51 per share Price / Book3.36Miscellaneous Outstanding Shares31,426,000Free FloatN/AMarket CapC$159.33 million OptionableNot Optionable Beta0.54 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (TSE:MDP) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the do...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredOn October 7th, your “safest” assets are at riskJeff Brown called Nvidia's rise of over 27,000 percent and warned in early 2024 that inflation would outlast W...Brownstone Research | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
